This site is intended for healthcare professionals
News

BeiGene announces Brukinsa approved in Australia for treatment of patients with Mantle Cell Lymphoma.

Read time: 1 mins
Last updated:11th Oct 2021
Published:11th Oct 2021
BeiGene announced that Brukinsa (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Condition: Mantle Cell Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights